Literature DB >> 27718136

Global chemotherapy development for gastric cancer.

Kazuto Harada1, Dilsa Mizrak Kaya1, Yusuke Shimodaira1, Jaffer A Ajani2.   

Abstract

To combat the dismal mortality rates from metastatic gastric adenocarcinoma (GAC), new drugs and treatment strategies are needed. Today, metastatic GAC is predominantly treated by empiric chemotherapy. Combination of two cytotoxic agents has become commonplace in North America, Europe, and Asia. Human epidermal growth factor 2 (HER2) overexpression (protein or gene copy numbers) has resulted in the addition of trastuzumab in the first-line chemotherapy combination in patients whose tumor is HER2 positive. The addition of trastuzumab in this select population has provided a modest survival advantage. In this review we trace the global development of systemic therapy in patients with metastatic GAC and ponder what lies in the future.

Entities:  

Keywords:  Chemotherapy; Gastric adenocarcinoma; Molecularly targeted drug

Mesh：

Year:  2016        PMID： 27718136     DOI： 10.1007/s10120-016-0655-8

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN： 1436-3291            Impact factor:   7.370


  83 in total

1.  Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

Authors:  Jaffer A Ajani; Miguel B Fodor; Sergei A Tjulandin; Vladimir M Moiseyenko; Yee Chao; Sebastiao Cabral Filho; Alejandro Majlis; Sylvie Assadourian; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Peter C Thuss-Patience; Albrecht Kretzschmar; Dmitry Bichev; Tillman Deist; Axel Hinke; Kirstin Breithaupt; Yasemin Dogan; Bernhard Gebauer; Guido Schumacher; Peter Reichardt
Journal:  Eur J Cancer       Date:  2011-10       Impact factor: 9.162

3.  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Authors:  J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

4.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

Authors:  Jung Hun Kang; Soon Il Lee; Do Hyoung Lim; Keon-Woo Park; Sung Yong Oh; Hyuk-Chan Kwon; In Gyu Hwang; Sang-Cheol Lee; Eunmi Nam; Dong Bok Shin; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Se Hoon Park
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

5.  Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

Authors:  Atsushi Ohtsu; Jaffer A Ajani; Yu-Xian Bai; Yung-Jue Bang; Hyun-Cheol Chung; Hong-Ming Pan; Tarek Sahmoud; Lin Shen; Kun-Huei Yeh; Keisho Chin; Kei Muro; Yeul Hong Kim; David Ferry; Niall C Tebbutt; Salah-Eddin Al-Batran; Heind Smith; Chiara Costantini; Syed Rizvi; David Lebwohl; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

6.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

7.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

Authors:  Shuichi Hironaka; Shinya Ueda; Hirofumi Yasui; Tomohiro Nishina; Masahiro Tsuda; Takehiko Tsumura; Naotoshi Sugimoto; Hideki Shimodaira; Shinya Tokunaga; Toshikazu Moriwaki; Taito Esaki; Michitaka Nagase; Kazumasa Fujitani; Kensei Yamaguchi; Takashi Ura; Yasuo Hamamoto; Satoshi Morita; Isamu Okamoto; Narikazu Boku; Ichinosuke Hyodo
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

Authors:  A F C Okines; A R Norman; P McCloud; Y-K Kang; D Cunningham
Journal:  Ann Oncol       Date:  2009-05-27       Impact factor: 32.976

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396
View more
  15 in total

1.  Comparison of treatment strategies and survival of early-onset gastric cancer: a population-based study.

Authors:  Chunmei Zhang; Ruiyi Tang; Hanlong Zhu; Xianxiu Ge; Yue Wang; Xue Wang; Lin Miao
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

2.  High-density lipoprotein, low-density lipoprotein and triglyceride levels and upper gastrointestinal cancers risk: a trans-ancestry Mendelian randomization study.

Authors:  Yanling Wu; Junyi Xin; Elizabeth A Loehrer; Xia Jiang; Qianyu Yuan; David C Christiani; Hanping Shi; Lingxiang Liu; Shuwei Li; Meilin Wang; Haiyan Chu; Mulong Du; Zhengdong Zhang
Journal:  Eur J Clin Nutr       Date:  2022-01-21       Impact factor: 4.884

3.  The Management and Prognostic Prediction of Adenocarcinoma of Appendix.

Authors:  Xin Xie; Zhangjian Zhou; Yongchun Song; Wenhan Li; Dongmei Diao; Chengxue Dang; Hao Zhang
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

4.  Actionable gene-based classification toward precision medicine in gastric cancer.

Authors:  Hiroshi Ichikawa; Masayuki Nagahashi; Yoshifumi Shimada; Takaaki Hanyu; Takashi Ishikawa; Hitoshi Kameyama; Takashi Kobayashi; Jun Sakata; Hiroshi Yabusaki; Satoru Nakagawa; Nobuaki Sato; Yuki Hirata; Yuko Kitagawa; Toshiyuki Tanahashi; Kazuhiro Yoshida; Ryota Nakanishi; Eiji Oki; Dana Vuzman; Stephen Lyle; Kazuaki Takabe; Yiwei Ling; Shujiro Okuda; Kohei Akazawa; Toshifumi Wakai
Journal:  Genome Med       Date:  2017-10-31       Impact factor: 11.117

Review 5.  Medical management of gastric cancer: a 2017 update.

Authors:  Nikolaos Charalampakis; Panagiota Economopoulou; Ioannis Kotsantis; Maria Tolia; Dimitrios Schizas; Theodore Liakakos; Elena Elimova; Jaffer A Ajani; Amanda Psyrri
Journal:  Cancer Med       Date:  2017-12-13       Impact factor: 4.452

6.  PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.

Authors:  Xiang'an Tian; Chengju Yang; Liguang Yang; Qinli Sun; Naiqing Liu
Journal:  Onco Targets Ther       Date:  2018-11-02       Impact factor: 4.147

7.  Management and prognostic prediction of appendiceal mucinous adenocarcinoma with peritoneal metastasis: a single center study in China.

Authors:  Ruiqing Ma; Bing Wang; Xichao Zhai; Yiyan Lu; Hongbin Xu
Journal:  BMC Cancer       Date:  2020-04-06       Impact factor: 4.430

8.  The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients.

Authors:  Long Yan; Hongbin Liu; Hongtao Li; Xiaopeng Han; Tingbao Cao; Chaoyang Wang; Gaitian Li
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 9.  Clinical significance of circulating tumor cells in blood from patients with gastric cancer.

Authors:  Takaaki Arigami; Yoshikazu Uenosono; Shigehiro Yanagita; Keishi Okubo; Takashi Kijima; Daisuke Matsushita; Masahiko Amatatsu; Hiroshi Kurahara; Kosei Maemura; Shoji Natsugoe
Journal:  Ann Gastroenterol Surg       Date:  2017-04-25

10.  Nomogram for predicting the survival of gastric adenocarcinoma patients who receive surgery and chemotherapy.

Authors:  Chao-Yang Wang; Jin Yang; Hao Zi; Zhong-Li Zheng; Bing-Hui Li; Yang Wang; Zheng Ge; Guang-Xu Jian; Jun Lyu; Xiao-Dong Li; Xue-Qun Ren
Journal:  BMC Cancer       Date:  2020-01-06       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.